BMJ Best Practice

参考文献

关键文献

Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v40-v55.

Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328-2334.

Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:1641-1647.

Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg. 2005;130:1413-1421.

Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):357S-360S.

Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5(suppl 4):348S-351S.

参考文章

1.  Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and association with subsequent malignancies. Int J Cancer. 2003;105:546-551.

2.  Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v40-v55.

3.  Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77:1860-1869.

4.  Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, eds. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1997:93-115.

5.  Muller-Hermelink HK, Strobel P, Zetti A, et al. Combined thymic epithelial tumors. In: Travis WD, Brambilla E, Muller-Hermeling HK, eds. Pathology and genetics: tumors of the lung, pleura, thymus and heart (WHO classification of tumors). Lyon, France: IARC Press; 2004:196-201.

6.  Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328-2334.

7.  Suadjian J, Enriquez P, Silverstein MN, et al. The spectrum of diseases associated with thymoma: coincidence or syndrome? Arch Intern Med. 1974;154:374-379.

8.  Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-1117.

9.  Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624-632.

10.  Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;75:878-885.

11.  Filosso PL, Actis Dato GM, Ruffini E, et al. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg. 2004;127:1215-1219.

12.  Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39:784-798.

13.  Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797-1810.

14.  Wudel LJ, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001;2:77-91.

15.  Marom EM. Imaging thymoma. J Thorac Oncol. 2010;5(suppl 4):296S-303S.

16.  Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869-876.

17.  Endo M, Nakagawa K, Ohde Y, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61:350-355.

18.  Howard FM, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526-538.

19.  Maher MM, Shepard JA. Imaging of thymoma. Semin Thorac Cardiovasc Surg. 2005;17:12-19.

20.  Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492.

21.  Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothorac Surg. 1994;8:251-253.

22.  Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5(suppl 4):304S-312S.

23.  Falkson CB, Bezjak A, Darling G, et al; Cancer Care Ontario. The management of thymoma: a systematic review and practice guideline. July 2014. http://www.cancercare.on.ca (last accessed 15 September 2017).

24.  Ettinger DS, Akerley W, Bepler G, et al; National Comprehensive Cancer Network. Thymic malignancies. J Natl Compr Canc Netw. 2010;8:1302-1315.

25.  Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg. 2008;86:673-684.

26.  Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002;74:1033-1037.

27.  Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:1641-1647.

28.  Giannopoulou A, Gkiozos I, Harrington KJ, et al. Thymoma and radiation therapy: a systematic review of medical treatment. Expert Rev Anticancer Ther. 2013;13:759-766.

29.  Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003;76:1866-1872.

30.  Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg. 2007;134:1477-1484.

31.  Loehrer PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010-2015.

32.  Riely GJ, Huang J. Induction therapy for locally advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):323S-326S.

33.  Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg. 2008;85:385-389.

34.  Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093-3099.

35.  Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg. 2005;130:1413-1421.

36.  Huang J, Rizk NP, Travis WD. Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg. 2009;138:26-31.

37.  Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):357S-360S.

38.  Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg. 2006;82:1234-1239.

39.  Eng TY, Thomas CR. Radiation therapy in the management of thymic tumors. Semin Thorac Cardiovasc Surg. 2005;17:32-40.

40.  Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5(suppl 4):348S-351S.

41.  Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893-902.

42.  Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789-796.

43.  Qureshi AI, Choudry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629-632.

44.  Kang SY, Lee JS, Choi JC, Kang JH. Myasthenia gravis appearing after thymectomy: a case report and review of the literature. J Clin Neurol. 2007;3:158-160.

45.  Nations SP, Wolfe GI, Amato AA, et al. Myasthenia gravis developing after removal of a thymoma. J Child Neurol. 1997;2:133-135.

46.  Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA. 2000;283:1142-1143.

使用此内容应接受我们的免责声明